First cases using Smith+Nephew’s new CATALYSTEM™ Primary Hip System completed; surgeons hail precision, efficiency and reproducibility
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces promising surgeon feedback from the first completed cases utilizing its new CATALYSTEM Primary Hip System. Designed to address the evolving demands of primary hip surgery - including the increased adoption of anterior approach procedures – the CATALYSTEM Primary Hip System features a triple-taper stem design with uniform proximal loading.1 The reduced distal stem geometry and shorter lengths are ideal for anterior approach but suitable for all approaches.2
The first surgical procedures using the CATALYSTEM Primary Hip System were completed last week in the United States by three prominent orthopaedic surgeons who commented on their experience utilizing the system for the first time.
“Smith+Nephew’s new CATALYSTEM Primary Hip System with RI.HIP NAVIGATION represents the beginning of a new era combining advanced technology and patient personalization that will, without doubt, enhance patient outcomes,” said Dr. Thorsten Seyler of Duke University.
The CATALYSTEM Primary Hip System also utilizes proprietary, patent-pending, ACCUBROACH◊ Technology delivering proven reproducibility between broach and implant giving confidence in predictable and reproducible stem seating.3,4
“The instruments were exceptionally user-friendly and ideal for the direct anterior approach,” commented George Haidukewych MD, Orlando Health, Orlando, Florida. “The broaches showed a significant improvement in performance, offering superior cutting and a more precise feel for rotational stability. In comparison to other implants I've used in recent years, these stand out as markedly better. Overall A-plus…it could not have gone better.”
Dr. Ran Schwarzkopf, Orthopedic Adult Hip and Knee Reconstruction Surgeon at NYU Langone Health commented, "The case went smoothly and exceeded all my expectations. It's the best anatomically fitting stem I've ever seen - it fit the patient's anatomy perfectly. The advantage of the broaches giving exact stem-to-broach positioning is unmatched in the industry.”
To learn more about Smith+Nephew’s new CATALYSTEM Primary Hip System for total hip arthroplasty, please visit https://www.smith-nephew.com/en/health-care-professionals/products/orthopaedics/catalystem
- ends –
Media Enquiries
Dave Snyder +1 (978) 749-1440
Smith+Nephew david.snyder@smith-nephew.com
References
- Smith + Nephew 2024. Finite Element Analysis of the CATALYSTEM Hip Stem Design. Internal Report. OR-24-025
- Smith + Nephew 2024. Surgeon Feedback on the CATALYSTEM Total Hip System. Internal Report. CSD.REC.24.001
- Smith + Nephew 2024. Cadaveric study of the repeatability of CATALYSTEM broach and femoral stem seating level. Internal Report. 10144794
- Smith + Nephew 2024. CATALYSTEM Accubroach Femur to Bone Interaction Design Rationale. Internal Report. 10142827
This document is provided for informational purposes and is not intended to serve as medical advice. It is the responsibility of healthcare professionals to determine and utilise the appropriate products and techniques according to their own clinical judgment for each of their patients.
The surgeon testimonials set out in this document represent the individual surgeon’s opinions, findings, beliefs, and/or experiences. Individual results will vary. The surgeons featured were involved in the development of CATALYSTEM and were compensated by Smith+Nephew for their time.
To review the information needed to understand and use CATALYSTEM safely and effectively, including indications for use, contraindications, effects, precautions, and warnings, please consult the product’s applicable Instructions for Use (IFU) prior to use.
Products featured may not be available in individual markets due to regulatory and/or medical practices. Please contact your Smith+Nephew representative if you have questions about availability of Smith+Nephew products in your area.
About Smith+Nephew
Smith+Nephew is a portfolio medical technology business focused on the repair, regeneration and replacement of soft and hard tissue. We exist to restore people’s bodies and their self-belief by using technology to take the limits off living. We call this purpose ‘Life Unlimited’. Our 18,000 employees deliver this mission every day, making a difference to patients’ lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global business units of Orthopaedics, Sports Medicine & ENT and Advanced Wound Management.
Founded in Hull, UK, in 1856, we now operate in more than 100 countries, and generated annual sales of $5.5 billion in 2023. Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN). The terms ‘Group’ and ‘Smith+Nephew’ are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.
For more information about Smith+Nephew, please visit www.smith-nephew.com and follow us on X, LinkedIn, Instagram or Facebook.
Forward-looking Statements
This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading profit margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: conflicts in Europe and the Middle East, economic and financial conditions in the markets we serve, especially those affecting healthcare providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal and financial compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and disposals, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; relationships with healthcare professionals; reliance on information technology and cybersecurity; disruptions due to natural disasters, weather and climate change related events; changes in customer and other stakeholder sustainability expectations; changes in taxation regulations; effects of foreign exchange volatility; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew's most recent annual report on Form 20-F, which is available on the SEC’s website at www. sec.gov, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew's expectations.
◊ Trademark of Smith+Nephew. Certain marks registered in US Patent and Trademark Office.
Latest directors dealings
- 21 hours ago Savannah Energy
- 23 hours ago Buccaneer Energy PLC
- 23 hours ago Savannah Energy
- 23 hours ago Carclo
- 23 hours ago Schroder Japan Growth Fund